Sherbrooke Park Advisers LLC Invests $177,000 in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Sherbrooke Park Advisers LLC acquired a new position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 26,230 shares of the company’s stock, valued at approximately $177,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of RXRX. Barclays PLC increased its stake in shares of Recursion Pharmaceuticals by 53.9% in the third quarter. Barclays PLC now owns 697,432 shares of the company’s stock worth $4,596,000 after purchasing an additional 244,278 shares in the last quarter. Arkadios Wealth Advisors purchased a new stake in shares of Recursion Pharmaceuticals in the fourth quarter worth $84,000. Brighton Jones LLC increased its stake in shares of Recursion Pharmaceuticals by 49.4% in the fourth quarter. Brighton Jones LLC now owns 20,261 shares of the company’s stock worth $137,000 after purchasing an additional 6,699 shares in the last quarter. Impact Partnership Wealth LLC purchased a new stake in shares of Recursion Pharmaceuticals in the fourth quarter worth $90,000. Finally, Exchange Traded Concepts LLC grew its stake in Recursion Pharmaceuticals by 101.6% during the fourth quarter. Exchange Traded Concepts LLC now owns 50,761 shares of the company’s stock valued at $343,000 after acquiring an additional 25,579 shares in the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on RXRX. Cowen reaffirmed a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Morgan Stanley cut their target price on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an “equal weight” rating for the company in a research note on Thursday, April 10th. Needham & Company LLC cut their target price on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday, May 6th. Finally, Leerink Partners cut their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a research note on Friday, February 28th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $7.60.

Recursion Pharmaceuticals Stock Performance

Shares of NASDAQ:RXRX opened at $4.55 on Wednesday. Recursion Pharmaceuticals, Inc. has a 52 week low of $3.79 and a 52 week high of $12.36. The stock has a market capitalization of $1.85 billion, a P/E ratio of -2.97 and a beta of 0.99. The firm has a fifty day simple moving average of $5.28 and a two-hundred day simple moving average of $6.56. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $14.75 million during the quarter, compared to analysts’ expectations of $18.12 million. During the same period in the previous year, the business earned ($0.39) earnings per share. The business’s quarterly revenue was up 7.2% on a year-over-year basis. On average, analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.